biosimilars

Patient group pushes FDA to improve biosimilar educationFDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
Three Barriers to Biosimilar AdoptionUnderstanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.
Expert Predictions: Generic Drug Costs, Biosimilar Impact, Policy ChangesHow are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.
Will biosimilars deliver on expectations?
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Autoimmune drug pipeline highlights
Autoimmune drug pipeline highlightsMore targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
A noteworthy margin of error in psoriasis?Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.
What oncologists say about new cancer treatment optionsA new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
Pfizer won't launch its second Remicade biosimilar in U.S.
Biosimilars for Cancer Drugs Move AheadBiosimilar to Herceptin Is Approved and Neulasta biosimilar does well in studies.
Four therapeutic areas to watch in 2018
Four therapeutic areas to watch in 2018Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.